N,N,N',N'-四(2-羟基乙基)壬烷二酰胺 | 52914-63-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: N,N,N',N'-四(2-羟基乙基)壬烷二酰胺
• 英文名称: Nonanedioic acid bis-[bis-(2-hydroxy-ethyl)-amide]
• 英文别名: N,N,N',N'-Tetrakis(2-hydroxyethyl)nonanediamide
• CAS: 52914-63-3
• 化学式: C₁₇H₃₄N₂O₆
• 分子量: 362.467
• InChiKey: PQHUNAMOLSBIAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  25
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  122
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  二乙醇胺 、 alkaline earth salt of/the/ methylsulfuric acid 生成 8-[Bis-(2-hydroxy-ethyl)-carbamoyl]-octanoic acid 2-(2-hydroxy-ethylamino)-ethyl ester 、 N,N,N',N'-四(2-羟基乙基)壬烷二酰胺
  参考文献：
  名称：

  Efimov; Bagrov; Kol'tsov, Doklady Chemistry, 1997, vol. 355, # 4-6, p. 169 - 174

  摘要：

  DOI：

文献信息

• ADELMIDROL FOR USE IN THE TREATMENT OF DISEASES SENSITIVE TO THE SPECIFIC AGONISM OF THE PPAR-GAMMA RECEPTOR
  申请人：EPITECH GROUP S.p.A.

  公开号：EP3162365A2

  公开（公告）日：2017-05-03

  The present invention relates to Adelmidrol for use in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system; fibrogenesis of the articular cartilages; chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis; Irritable Bowel Syndrome (IBS); diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung; eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.

  本发明涉及阿地米罗（Adelmidrol），用于治疗以人或动物体内 PPAR-gamma 受体特异性激动不足为特征的疾病，尤其是用于治疗机械性、毒性、先天性、退行性关节软骨病，或主要与不属于骨关节系统的器官和组织相关的炎症现象；关节软骨的纤维增生；慢性炎症性肠病（IBD），如克罗恩病和溃疡性结肠炎；肠易激综合征（IBS）；以结缔组织异常纤维化为特征的疾病，如系统性硬化症，尤其是皮肤和肺部；以血管生成、纤维化、炎症和氧化应激为特征的眼部疾病。
• ADELMIDROL FOR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY AN ABNORMAL FIBROSIS OF THE CONNECTIVE TISSUE OF THE LUNG
  申请人：EPITECH GROUP S.p.A.

  公开号：EP3827819A1

  公开（公告）日：2021-06-02

  The present invention concerns Adelmidrol for use in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals selected from diseases characterized by an abnormal fibrosis of the connective tissue of the lung.

  本发明涉及 Adelmidrol，用于治疗以人或动物体内 PPAR-gamma 受体特异性激动不足为特征的疾病，这些疾病选自以肺结缔组织异常纤维化为特征的疾病。
• Efimov; Bagrov; Kol'tsov, Russian Journal of Organic Chemistry, 1996, vol. 32, # 1, p. 41 - 43
  作者：Efimov、Bagrov、Kol'tsov、Andreeva、Kolyamshin

  DOI：——

  日期：——
• Aqueous thermosetting coating compositions containing a water-soluble hydroxy-amido compound
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0028469B1

  公开（公告）日：1983-11-02
• USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS
  申请人：Innovet Italia S.r.l.

  公开号：EP1115392A2

  公开（公告）日：2001-07-18